Pharma Pulse: FDA Expands Pediatric Juxtapid Approval and Novo Nordisk Invests €432M in Oral GLP-1 Scaling

Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast in which we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I'm your host, and let's get into today's headlines.

• The FDA has expanded the indication for lomitapide, marketed as Juxtapid, to include pediatric patients aged 2 and older with homozygous familial hypercholesterolemia, or HoFH. This landmark decision addresses an ultra-rare genetic disorder that causes dangerously high LDL levels starting at birth. Clinical data demonstrated a 53.5% mean reduction in bad cholesterol when added to existing therapies. Due to risks of hepatotoxicity, the drug remains available only through a restricted REMS program.
• Meanwhile, Novo Nordisk is scaling its global manufacturing capacity with a €432 million ($502.6 million) investment to retrofit its facility in Athlone, Ireland. Designated as a primary international manufacturing hub, the site will boost oral GLP-1 production by 2028 to strengthen supply-chain resilience. This investment coincides with a strategic partnership with Vivtex, utilizing AI-enabled modeling and robotics to identify oral biologic formulations with improved intestinal absorption.

That’s it for this episode of Pharma Pulse. For more insights on trends transforming pharmaceutical access and care delivery, visit pharmaceuticalcommerce.com.

Thanks for listening—until next time, stay well and stay informed.

You can catch Pharma Pulse directly on Audioboom, Spotify, or iHeart.